The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians// - today said physicians should consider lowering the dose of the steroid dexamethasone when treating patients with multiple myeloma.
High dose dexamethasone has been used as standard therapy for the treatment of myeloma alone and in combination with other drugs. However, interim findings from a large ongoing clinical trial of REVLIMID plus dexamethasone in newly diagnosed patients, suggest lowering the "dex" dose may not only reduce side effects, but also may improve survival.
The trial, known as E4A03, is sponsored by the National Cancer Institute and led by the Eastern Cooperative Oncology Group (ECOG). Based on these findings, ECOG has suspended further patient enrollment for this trial and has recommended that lower dose "dex" be considered for patients currently being treated on the high dose arm of the trial. Because of the public health implications, these findings are being made public immediately. The complete details will be presented at a cancer conference later this spring.
"Improved survival with low dose 'dex' and REVLIMID is an important finding because it further improves the outcome for an already successful treatment, while low dose dexamethasone is better tolerated by patients," said Brian G. M. Durie, M.D., chairman and co-founder of the International Myeloma Foundation. "We are recommending that physicians consider these findings when treating their patients across all stages of myeloma and that patients discuss these findings with their physicians."
Susie Novis, president and co-founder of the IMF, added, "These findings may also have wider implications for cancer treatments because they challenge the traditional notion that patients should be treated with the highest dose of medicine they can tolerate. Now we have evidence thatPage: 1 2 3 Related medicine news :1
. Clinical trials need to be more frank2
. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses 3
. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics4
. Clinical Comparisons Between ADHD Drugs Are Less5
. A Novel System For Clinical Banking Of Umbilical Cord Blood 6
. Clinical Renal Trails Do Not Have Sufficient Women Participants7
. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment8
. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand9
. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients10
. Cancer Clinical Research in India11
. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care